Parkinson’s disease anxiety is associated with Lewy bodies in the Anterior Cingulate
Objective: The goal of this study is to determine if there is an association between anxiety and the presence and regional distribution of Lewy bodies…Development of a biomarker for Parkinson’s disease by measuring alpha-synuclein oligomers in cerebrospinal fluid with ultrasonication-induced amyloid fibril formation
Objective: To establish a new technique quantifying misfolded alpha-synuclein (αSyn) oligomers in the CSF and to investigate their clinical - pathological significances in Parkinson’s disease…Microarray analysis upon an synthetic α-synuclein induced model reveals some susceptibility genes in Parkinson’s disease
Objective: To uncover new disease-associated genes and their relevant mechanisms in the pathogenetic process of neurodegenerative disorders, we carried out a gene microarray analysis based…Cell and animal models lacking RAB39B show biochemical and behavioural phenotypes that model aspects of Parkinson’s disease
Objective: To determine the pathogenic mechanisms underlying RAB39B-mediated Parkinson’s disease (PD). Background: PD is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the…Effects of JN403, an α-7-nicotine-acetylcholine-receptor (α7-nAChR) agonist on human alpha-synuclein-mediated in vitro and in vivo models of Parkinson’s disease
Objective: To investigate whether JN403, a novel selective agonist of α-7-nicotine-acetylcholine-receptors (α7-nAChRs) can suppress inflammation and toxicity in human alpha-synuclein (αSyn) induced in vitro and…Identification and analysis of differential miRNA in exosomes of dopaminergic neurons overexpressing α-synuclein
Objective: The aim of this study was to compare the miRNA expression in secreted exosomes from dopaminergic neurons overexpressing α-synuclein with healthy neurons. Background: Exosomes,…Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)
Objective: To characterize the distribution of alpha-synuclein (aSyn) pathology in multiple tissues and body fluids within the same Parkinson’s disease (PD) subjects and compared to…Oral treatment with JNX3001 protects dopaminergic function in a non-human primate model of Parkinson’s disease alpha-synucleinopathy
Objective: We evaluated the efficacy of JNX3001 in an aSyn-based macaque model with plasma exposures associated with efficacy in rodents. Background: Alpha-synuclein (aSyn) deposition is…Investigating the influence of alpha-synuclein promoter (Rep1) polymorphism on cognition, disability and plasma alpha-synuclein levels in Parkinson’s disease
Objective: We sought to investigate the relationship between SNCA Rep1 allele length and cognitive, motor and disability scores in PD, as well with plasma alpha-synuclein…Insulin degrading enzyme, a novel key protein against alpha-synuclein oligomers formation?
Objective: The objective of this work is to study the interaction between α-synuclein and the insulin degrading enzyme in the pancreas of subjects with synucleinopathies.…
- « Previous Page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- …
- 60
- Next Page »